Adagene Appoints Immuno-Oncology Pioneer, Axel Hoos, M.D., Ph.D., as Executive Advisor
1. Adagene appoints Dr. Axel Hoos as Executive Advisor. 2. ADG126 is undergoing clinical trials for cancer immunotherapy. 3. CTLA-4 targeting may improve treatment for cold tumors. 4. Dr. Hoos has a strong background in immuno-oncology.